Trial of Vacuum Assisted Closure® Therapy in Amputation Wounds of the Diabetic Foot

Phase 4

Completed

• Conditions: Diabetic Foot

• Registration Number: NCT00224796
• Lead Sponsor: KCI USA, Inc

Brief Summary

The purpose of this study is to compare the effectiveness of Vacuum Assisted Closure® (V.A.C.®) Therapy to moist wound therapy of amputation wounds of the diabetic foot. The primary objective is to determine the effect of V.A.C.® Therapy on the incidence of complete wound closure. Secondary objectives include evaluating the acceleration of wound closure, facilitation of surgical closure, incidence of foot salvage, and incidence of wound complications.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-05
• Study First Submitted: 2005-09-21
• Study First Submitted QC: 2005-09-21
• Study First Posted: 2005-09-23
• Study Completion: 2005-10
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-27
• Last Update Posted: 2024-12-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 146

Inclusion Criteria

1. Presence of a diabetic foot amputation wound up to the transmetatarsal region of the foot

2. Evidence of adequate perfusion by one of the following on the affected extremity, (within the past 60 days):

   • Dorsum transcutaneous oxygen test (TcPO2) with results of ≥30 mmHg, or
   • Ankle brachial index (ABIs) with results of ≥0.7 and ≤1.2 and toe pressures with results of ≥30 mmHg, or
   • Doppler arterial waveforms, which are triphasic or biphasic at the ankle in the affected leg.

3. Age ≥ 18 years of age

4. HbA1c ≤ 12% (collected within the last 90 days.)

5. Evidence of adequate nutrition by one of the following:

   • Lab results reflecting Pre-Albumin ≥16 mg/dl and Albumin level is ≥3 g/dl (during the seven days prior to the study period), or
   • A nutritional consult will be done and with appropriate supplementation started. Proper documentation on (case report forms)CRFs is needed.

Exclusion Criteria

1. Patients with recognized active Charcot abnormalities of the foot, as evidence by clinical symptoms that interfere with either randomized treatment group
2. Wounds resulting from electrical, chemical, or radiation burns, or venous insufficiency
3. Untreated infection or cellulitis at site of target wound
4. Presence of untreated osteomyelitis
5. Collagen vascular disease
6. Malignancy in the wound
7. Presence of necrotic tissue in the wound
8. Uncontrolled hyperglycemia
9. Concomitant medications that include (washout period of 30 days for corticosteroids, immunosuppressive medications, or chemotherapy)
10. Prior V.A.C.® therapy within 30 days.
11. Current or prior normothermic (Warm-UP®) or hyperbaric oxygen (HBO) therapy within 30 days.
12. Current or prior treatment with recombinant or autologous growth factor products within the past 30 days. (Examples: Regranex or Procuren)
13. Current or prior treatment with skin or dermal substitutes and dressings (Examples: Apligraf, Dermagraft, or Integra) with living cells capable of producing growth factors (Example: Oasis) within the past 30 days.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
To determine the effect of V.A.C. ® Therapy on the incidence of complete wound closure.

Secondary Outcome Measures

Name	Time	Method
To determine the incidence of foot salvage, as defined by retention of transmetatarsal amputation with no further revisions at end of study
To determine the incidence of complications
To determine the effect of V.A.C. ® Therapy on the accelerated wound closure or facilitation of surgical closure
To determine the change in wound area over time
To determine the effect of V.A.C. ® Therapy on the quality of life